UK-based inhaler developer Merxin Ltd has been awarded a 2026 King’s Award for Enterprise for Innovation, the company announced. Merxin, which is headquartered in King’s Lynn, UK, was launched in 2015 . The award announcement highlighted the company’s MRX004 soft mist inhaler; other Merxin devices include the MRX003 capsule-based DPI and the MRX006 multi-dose DPI.
Merxin Chief Business Officer Philippe Rogueda commented, “It is a proud moment for everyone at Merxin Ltd and a testament to ten years of outstanding innovation by an exceptional team. We are deeply honored by the recognition from His Majesty The King and the Prime Minister. We are excited about what this milestone means for our future. Thank you to everyone who has supported our journey..”
In addition to news of the award, Merxin has announced that former Bespak Chief Commercial Officer Peter Hirst will serve part time as the company’s Head of Business Development. Prior to the Bespak position, Hirst served in executive roles in business development for OINDP-related companies over several decades, including positions at Recipharm prior to the spinout of Bespak; Vectura, and Pharmaceutical Profiles.
Rogueda said, “Peter brings decades of inhaled drug delivery experience; from his PhD on cystic fibrosis at Bath, through senior commercial and scientific roles at Pharmaceutical Profiles, Vectura, and Bespack, to years of consulting across the industry. His appointment strengthens our commercial leadership as we advance our DPI and SMI platforms towards new therapies.”
Read the Merxin announcement of the King’s Award
Read the Merxin announcement of new Head of Business Development
